Literature DB >> 15526105

Urotensin II stimulates plasma extravasation in mice via UT receptor activation.

Raffaella Vergura1, Valeria Camarda, Anna Rizzi, Martina Spagnol, Remo Guerrini, Girolamo Calo', Severo Salvadori, Domenico Regoli.   

Abstract

The peptide urotensin II (U-II) is the cognate ligand of the G-protein coupled receptor UT (formerly GPR14). A role in the regulation of cardiovascular functions has been proposed for this novel peptide/receptor system. In the present study, we evaluated the ability of U-II to induce plasma extravasation in mice and attempted to characterize the receptor involved using the novel UT receptor ligand, [Orn(8)]U-II. The Evans blue technique was used to quantify plasma extravasation. U-II (0.01, 0.1, 1 and 10 nmol/kg) dose-dependently stimulated plasma extravasation in airways, gastrointestinal and urogenital tract tissues from mice, but not in the skin. In most tissues, the dose/response curves to U-II were bell shaped with the maximal effect induced by 1 nmol/kg. [Orn(8)]U-II at 30 nmol/kg was per se either inactive or produced a non-significant increase in plasma extravasation; in the presence of 30 nmol/kg [Orn(8)]U-II, the effects of 1 nmol/kg U-II were always reduced and, in some tissues, abolished. The present findings demonstrate that U-II promotes plasma extravasation in various mouse vascular regions via activation of UT receptors. The mouse plasma extravasation assay will be a useful tool in future studies aimed at characterizing the pharmacological features of novel UT receptor ligands in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15526105     DOI: 10.1007/s00210-004-0991-9

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  41 in total

1.  High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man.

Authors:  Ian B Wilkinson; Jonathan T Affolter; Sanne L de Haas; M Paola Pellegrini; Judith Boyd; Matthew J Winter; Richard J Balment; David J Webb
Journal:  Cardiovasc Res       Date:  2002-02-01       Impact factor: 10.787

2.  Substance P and bradykinin stimulate plasma extravasation in the mouse gastrointestinal tract and pancreas.

Authors:  M Figini; C Emanueli; E F Grady; K Kirkwood; D G Payan; J Ansel; C Gerard; P Geppetti; N Bunnett
Journal:  Am J Physiol       Date:  1997-04

3.  Urotensin II evokes potent vasoconstriction in humans in vivo.

Authors:  Felix Böhm; John Pernow
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

4.  Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents.

Authors:  Valeria Camarda; Anna Rizzi; Girolamo Calò; Gabrielle Gendron; Stephan I Perron; Evi Kostenis; Paolo Zamboni; Francesco Mascoli; Domenico Regoli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2001-11-20       Impact factor: 3.000

5.  Structure-activity relationship study on human urotensin II.

Authors:  Remo Guerrini; Valeria Camarda; Erika Marzola; Marika Arduin; Girolamo Calo; Martina Spagnol; Anna Rizzi; Severo Salvadori; Domenico Regoli
Journal:  J Pept Sci       Date:  2005-02       Impact factor: 1.905

6.  Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey.

Authors:  Nabil A Elshourbagy; Stephen A Douglas; Usman Shabon; Stephen Harrison; Graham Duddy; Jan L Sechler; Zhaohui Ao; Beverly E Maleeff; Diane Naselsky; Jyoti Disa; Nambi V Aiyar
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

7.  Congestive heart failure and expression of myocardial urotensin II.

Authors:  Stephen A Douglas; Lara Tayara; Eliot H Ohlstein; Nadine Halawa; Adel Giaid
Journal:  Lancet       Date:  2002-06-08       Impact factor: 79.321

8.  Contraction of major artery segments of rat by fish neuropeptide urotensin II.

Authors:  H Itoh; Y Itoh; J Rivier; K Lederis
Journal:  Am J Physiol       Date:  1987-02

9.  The expression of urotensin II receptor (U2R) is up-regulated by interferon-gamma.

Authors:  Magdalena Birker-Robaczewska; Céline Boukhadra; Rolf Studer; Célia Mueller; Christoph Binkert; Oliver Nayler
Journal:  J Recept Signal Transduct Res       Date:  2003       Impact factor: 2.092

10.  Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes.

Authors:  D Pearson; J E Shively; B R Clark; I I Geschwind; M Barkley; R S Nishioka; H A Bern
Journal:  Proc Natl Acad Sci U S A       Date:  1980-08       Impact factor: 11.205

View more
  8 in total

1.  In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II(4-11) (UFP-803).

Authors:  Valeria Camarda; Martina Spagnol; Wei Song; Raffaella Vergura; Adelheid L Roth; Jonathan P Thompson; David J Rowbotham; Remo Guerrini; Erika Marzola; Severo Salvadori; Paolo Cavanni; Domenico Regoli; Stephen A Douglas; David G Lambert; Girolamo Calò
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 2.  The role of urotensin II in cardiovascular and renal physiology and diseases.

Authors:  Yi-Chun Zhu; Yi-Zhun Zhu; Philip Keith Moore
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

3.  Biochemical and pharmacological characterization of nuclear urotensin-II binding sites in rat heart.

Authors:  N D Doan; T T M Nguyen; M Létourneau; K Turcotte; A Fournier; D Chatenet
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

4.  Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity.

Authors:  Wei Song; John McDonald; Valeria Camarda; Girolamo Calo; Remo Guerrini; Erika Marzola; Jonathan P Thompson; David J Rowbotham; David G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-04-05       Impact factor: 3.000

Review 5.  Urotensin-II and cardiovascular diseases.

Authors:  Nicolas Bousette; Adel Giaid
Journal:  Curr Hypertens Rep       Date:  2006-12       Impact factor: 5.369

6.  Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375.

Authors:  Stephen A Douglas; David J Behm; Nambi V Aiyar; Diane Naselsky; Jyoti Disa; David P Brooks; Eliot H Ohlstein; John G Gleason; Henry M Sarau; James J Foley; Peter T Buckley; Dulcie B Schmidt; William E Wixted; Katherine Widdowson; Graham Riley; Jian Jin; Timothy F Gallagher; Stanley J Schmidt; Lance Ridgers; Lisa T Christmann; Richard M Keenan; Steven D Knight; Dashyant Dhanak
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

Review 7.  Targeting of G-protein coupled receptors in sepsis.

Authors:  Abdul Rehman; Noor Ul-Ain Baloch; John P Morrow; Pál Pacher; György Haskó
Journal:  Pharmacol Ther       Date:  2020-03-19       Impact factor: 12.310

Review 8.  The G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features.

Authors:  Hélène Castel; Laurence Desrues; Jane-Eileen Joubert; Marie-Christine Tonon; Laurent Prézeau; Marie Chabbert; Fabrice Morin; Pierrick Gandolfo
Journal:  Front Endocrinol (Lausanne)       Date:  2017-04-25       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.